eli lily glp-1 Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Lilly's GLP-1 pill outperforms Novo's

Glucagon stimulates hepatic glucose production, which can have adverse effects on plasma glucose concentrations that are offset by the beneficial effects of weight loss, and decreases intrahepatic triglyceride content (mediated by increased intrahepatic triglyceride lipolysis, fatty acid oxidation, and ketogenesis and decreased de novo lipogenesis) and decreases plasma LDL-cholesterol concentration (mediated by increased hepatic LDL receptor activity)

A patient who loses a large amount of total weight but also loses too much muscle may feel weaker, colder, less energetic, or more prone to weight regain

The appetite suppression associated with semaglutide can be quite significant

Diz-Chaves Y, Herrera-Prez S, Gonzlez-Matas LC, Lamas JA, Mallo F

Its in the agenda!